228. 閉塞性細気管支炎 Bronchiolitis obliterans Clinical trials / Disease details

臨床試験数 : 97 / 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 156

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05413356 (ClinicalTrials.gov)	June 1, 2022	7/6/2022	Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome	Ruxolitinibfor Newly Diagnosed Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem ...	Bronchiolitis Obliterans Syndrome;Hematologic Malignancy	Drug: Ruxolitinib	First Affiliated Hospital of Zhejiang University	Second Affiliated Hospital, School of Medicine, Zhejiang University;Zhejiang Provincial People's Hos ...	Recruiting	18 Years	65 Years	All	50	Phase 2	China
2	NCT04908735 (ClinicalTrials.gov)	November 12, 2021	26/5/2021	Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant	Ruxolitinib for Early Lung Dysfunction After HSCT: a Phase II Study	Hematopoietic Stem Cell Transplant (HSCT);Bronchiolitis Obliterans (BO)	Drug: Ruxolitinib	Children's Hospital Medical Center, Cincinnati	NULL	Recruiting	5 Years	25 Years	All	40	Phase 2	United States
3	NCT03674047 (ClinicalTrials.gov)	April 19, 2019	14/9/2018	Ruxolitinibfor Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplan ...	A Phase II Study of Ruxolitinibfor Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopo ...	Other Cancer	Drug: ruxolitinib	Massachusetts General Hospital	Incyte Corporation	Recruiting	18 Years	75 Years	All	50	Phase 2	United States

First Previous1Next Last